Abstract: Embodiments of the present invention disclose a current source converter differential protection method, including: sampling, by a relay protection device, secondary side currents of current transformers on two sides of a protected current source converter, to obtain incomer-side three-phase currents, and outgoer-side three-phase currents; rectifying the incomer-side three-phase currents and the outgoer-side three-phase currents, to obtain an incomer-side input current and an outgoer-side output current which are equivalent; converting the incomer-side input current and the outgoer-side output current according to a current ratio of the current transformers on the two sides, to acquire a transient differential current and a transient restraint current; acquiring a differential current and a restraint current according to the transient differential current and the transient restraint current; and achieving differential protection according to the differential current and the restraint current.

Abstract: A relay protection method against LC parallel circuit detuning faults comprises the steps of: a relay protection device samples a current of a parallel LC, that is, a reactor and a capacitor, and samples a total current flowing through the whole LC; convert the current of the reactor into a current of an equivalent capacitor; calculate amplitudes of the current of the equivalent capacitor and a current of a realistic capacitor and calculate an amplitude of the total current flowing through the LC; calculate a current amplitude ratio of the equivalent capacitor to the realistic capacitor; and when the amplitude of the total current flowing through the LC is large enough, send an alarm signal or a trip after a setting time delay if the current ratio exceeds a preset upper and lower limit range. Also provided is a corresponding relay protection device.

Abstract: Embodiments of the present invention disclose a current source converter differential protection method, including: sampling, by a relay protection device, secondary side currents of current transformers on two sides of a protected current source converter, to obtain incomer-side three-phase currents, and outgoer-side three-phase currents; rectifying the incomer-side three-phase currents and the outgoer-side three-phase currents, to obtain an incomer-side input current and an outgoer-side output current which are equivalent; converting the incomer-side input current and the outgoer-side output current according to a current ratio of the current transformers on the two sides, to acquire a transient differential current and a transient restraint current; acquiring a differential current and a restraint current according to the transient differential current and the transient restraint current; and achieving differential protection according to the differential current and the restraint current.

Abstract: A separate domain selection function is utilized as the first function in a communication path for a communication that is to be connected to a user device registered in a first network or a second network. If a result of the domain selection function indicates call control should be maintained by first network (e.g., user device is registered with first network or a network with which first network has a control relationship), call control of the communication remains with first network. If the result of the domain selection function indicates the user device is registered with second network, call control is suspended by the first network, which allows the communication to bypass the first network.

Abstract: A separate domain selection function is utilized as the first function in a communication path for a communication that is to be connected to a user device registered in a first network or a second network. If a result of the domain selection function indicates call control should be maintained by first network (e.g., user device is registered with first network or a network with which first network has a control relationship), call control of the communication remains with first network. If the result of the domain selection function indicates the user device is registered with second network, call control is suspended by the first network, which allows the communication to bypass the first network.

Abstract: The present invention provides conjugates formed between toxins and sugars and toxins and peptides, such as antibodies. In an exemplary embodiment, a toxin-sugar construct is conjugated to an antibody through an intact glycosyl linking group.

Abstract: Aspects describe a separate domain selection function that is utilized as the first function in a communication path for a communication that is to be connected to a user device registered in a first network or a second network. If a result of the domain selection function indicates call control should be maintained by first network (e.g., user device is registered with first network or a network with which first network has a control relationship), call control of the communication remains with first network. If the result of the domain selection function indicates the user device is registered with second network, call control is suspended by the first network, which allows the communication to bypass the first network.

Abstract: The present invention provides conjugates formed between toxins and sugars and toxins and peptides, such as antibodies. In an exemplary embodiment, a toxin-sugar construct is conjugated to an antibody through an intact glycosyl linking group.

Abstract: The present invention provides polypeptides that include an O-linked glycosylation site that is not present in the wild-type peptide. The polypeptides of the invention include glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. Also provided are methods of making the peptides of the invention and methods, pharmaceutical compositions containing the peptides and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a peptide of the invention sufficient to achieve the desired response.

Abstract: A joining device is provided for rails of a baby bed, in which the joining connects two adjacent rail tubes of the rail, where an end of each of the rail tubes is pivotally connected to the joining device. The joining device is formed as a saddle part in a shape having two upstanding side walls and an arched portion connected between top edges of the two side walls. The joining device further has a smooth contact face formed on each of the two sides of the arched portion and a smoothly trimmed face connected to the smooth contact face, so that the tube walls of the rail tubes are contacted with the smooth contact faces when the rail tubes are pivotally rotated close to the two sides of the arched portion.

Abstract: Aspects describe a separate domain selection function that is utilized as the first function in a communication path for a communication that is to be connected to a user device registered in a first network or a second network. If a result of the domain selection function indicates call control should be maintained by first network (e.g., user device is registered with first network or a network with which first network has a control relationship), call control of the communication remains with first network. If the result of the domain selection function indicates the user device is registered with second network, call control is suspended by the first network, which allows the communication to bypass the first network.

Abstract: The present invention provides polypeptides that include an O-linked glycosylation site that is not present in the wild-type peptide. The polypeptides of the invention include glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. Also provided are methods of making a glycoconjugate, methods of isolating a glycoconjugate from a reaction mixture, pharmaceutical compositions containing a glycoconjugate, and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a glycoconjugate sufficient to achieve the desired response.

Abstract: The present invention provides conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.

Abstract: Novel synthetic gangliosides and pharmaceutical compositions containing such synthetic gangliosides are described. Methods of making the novel synthetic ganglioside compounds and compositions as well as their use in the field of neuroprotection is also described.

Abstract: Novel synthetic glycosphingolipids and pharmaceutical compositions containing such synthetic glycosphingolipids are described. Methods of making the novel synthetic glycosphingolipid compounds and compositions as well as their use in the field of neuroprotection and cancer treatment is also described.

Abstract: Novel synthetic gangliosides and pharmaceutical compositions containing such synthetic gangliosides are described. Methods of making the novel synthetic ganglioside compounds and compositions as well as their use in the field of neuroprotection and cancer treatment is also described.

Abstract: A canopy device includes two connecting seats, a canopy, and at least one elongated supporting member for supporting the canopy. The connecting seats are adapted to be mounted to a baby care apparatus. The supporting member has two opposite ends mounted respectively to the connecting seats, and at least one flexibility-increased lengthwise segment more flexible than a remaining portion of the supporting member.

Abstract: Novel synthetic gangliosides and pharmaceutical compositions containing such synthetic gangliosides are described. Methods of making the novel synthetic ganglioside compounds and compositions as well as their use in the field of neuroprotection and cancer treatment is also described.

Abstract: Disclosed is a joining device for the rails of a baby bed, in which the joining device is adapted for connecting two adjacent rail tubes of the rail and an end of each of the rail tubes is pivotally connected to said joining device, said joining device is formed as a saddle part in a shape, the joining device of a baby bed is characterized in that two outer edges of an iron plate at two ends of two shorter sides of an arched portion of said joining device are processed such that they are bent downwardly so as to be formed as smooth contact faces, and each of the backsides of said contact faces is further subject to a trimming process so as to be formed as a smoothly trimmed face in order to prevent a possibility that a fabric covering is directly cut off or broken when the fabric covering covered on a bed frame is gripped between the rail tubes and the arched portion of said joining device, and a possibility of generating an indent due to friction or pressing since the tube walls of said rail tubes are ramme

Abstract: The present invention provides polypeptides that include an O-linked glycosylation site that is not present in the wild-type peptide. The polypeptides of the invention include glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. Also provided are methods of making the peptides of the invention and methods, pharmaceutical compositions containing the peptides and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a peptide of the invention sufficient to achieve the desired response.